BioSpace News Archive

Agreement Will Enable MYOS to Significantly Expand the Reach of its Veterinary Business

Funding will advance study to quantify protein-based biomarker for the disease

52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study ( NCT03583372 ) and data by age groups from the 12-week placebo-controlled EMPOWUR study ( NCT03492281 ) will be pr

Merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing. Even at low concentrations of both drugs significant reduction in viral production occurs. Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch BioSig Technologies, Inc. (Nasdaq: BSGM ) today

Recursion , a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to gain rights to TAK-733, a clinical-stage MEK inhibitor, and develop it for the treatment of a hereditary cancer syndrome and related areas of oncology. “TAK-733 is a great example of the power of our approach to decode challenging

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will present new efficacy and cardiovascular safety data from the Phase 3 HERO study of once-daily, oral relugolix (120 mg) in men with advanced prostate cancer at the American Society of Clinical Oncology (ASCO)’s upcoming ASCO20 Virtual Scientific Program , to be held May 29-31, 2020. The new data will be pre

Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID19 vaccine.

BIO International transitions to virtual format known as BIO Digital due to COVID-19 pandemic

Envafolimab Demonstrated a 30% Confirmed Objective Response Rate (ORR) by RECIST by Independent Central Review in Patients with Advanced Refractory MSI-H/dMMR Colorectal and Gastric Cancer ORR and Other Data will be Updated at ASCO TRACON Expects to Initiate its Pivotal ENVASARC Trial of Envafolimab in Sarcoma in Second Half of 2020 SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development

OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that its abstract on the use of advanced bioinformatic analysis and machine learning tools on plasma proteomics in order to predict outcomes of immunotherapy-treated melanoma patients was accepted for the American Society of Clinical Oncology (ASCO) 2020 Virtual Poster Discussion Session.